Atlas Trials

A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

Clinical trial NCT07163481 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07163481
Sponsor
Hunan Cancer Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Stage IV (Metastatic) Breast Cancer
Start date
2025-10-01
Primary completion
2026-12-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.